pharma · BIOCON
Biocon
Biocon: PE above historical average. NARROW LEADERSHIP regime. sector leading.
Price
₹425.35
Price 2026-07-30
5 day
-1.91%
Short-term move
1 month
+1.81%
Medium-term
Regime
NARROW LEADERSHIP
62% confidence
Market cap
₹66.3k Cr
inflow sector flow
Market Intelligence Analyst
Understand today's market in about 2 minutes.
“How does today's NARROW LEADERSHIP regime affect Biocon (BIOCON) in the pharma sector?”
Price chart
₹432
+21.74% over period
About Biocon
Biocon Limited, together with its subsidiaries, manufactures biotechnology products and offers research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics; Biosimilars; and Contract Research, Development and Manufacturing Organization (CRDMO) segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, central nervous system, anti-cancer/oncology, multiple sclerosis, immunosuppressants, and specialty molecules; and biosimilars products for oncology, diabetes, and immunology therapeutic areas. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal health, consumer goods, and specialty chemical industries, as well as academic institutions, non-profit organizations, and government agencies. In addition, the company offers enzyme, biopharmaceutical, and medicinal goods; contract research and manufacturing services; clinical research; and business support and development, and marketing services. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.
At a Glance
RSI pattern warning
RSI oversold bounces for this stock succeeded only 0% of the time (avg -9.2% over 14 days) — not a reliable pattern.
52-week position
Trading at 96.6% of 52-week high
Technicals
RSI 14
54.8
Trend
uptrend
50 DMA
Above
200 DMA
Above
Key metrics
P/E ratio
145.3
57th pct · 7 quarterly points (limited history)
P/B
1.9
ROE
1.1%
Below-average profitability — 1.1% ROE
Market cap
₹66.3k Cr
Revenue growth
230.0% YoY
Promoter
53.8%
52-week range
₹331 – ₹440.4
96.6% of high
RSI (14)
54.8
uptrend
vs 50 DMA
Above
DMA ₹422.47
Coverage
100/100
HIGH
Quick Take
Biocon: PE above historical average. NARROW LEADERSHIP regime. sector leading.
Peer comparison
| Stock | Price | 5D | P/E | ROE | Rev growth | Mcap |
|---|---|---|---|---|---|---|
| DIVISLAB Divi's Laboratories | ₹7,835 | +7.7% | 70 | 16.2% | 950% | ₹1.8L Cr |
| CIPLA Cipla | ₹1,466.4 | +5.3% | 30.2 | 11.7% | -210% | ₹1.2L Cr |
| DRREDDY Dr. Reddy's Laboratories | ₹1,144.8 | -1.8% | 26.5 | 11.8% | -1160% | ₹1.1L Cr |
| AUROPHARMA Aurobindo Pharma | ₹1,576.3 | +3.5% | 26.3 | 9.9% | 560% | ₹91.1k Cr |
| ALKEM Alkem Laboratories | ₹5,816.5 | +3.8% | 29.4 | 17.6% | 1460% | ₹67.8k Cr |
| GLENMARK Glenmark Pharmaceuticals | ₹2,190.3 | -0.7% | 47 | 14.1% | 1430% | ₹63.9k Cr |
| GLAND Gland Pharma | ₹2,517 | +5.9% | 40.9 | 10.5% | 2230% | ₹42.1k Cr |
| JBCHEPHARM J B Chemicals | ₹2,408.9 | +0.0% | 54.5 | 18.7% | -480% | ₹38.9k Cr |
| BIOCON Biocon | ₹425.35 | -2.3% | 145.3 | 1.1% | 230% | ₹66.3k Cr |
Tensions to watch
Promoter holding at 53.8% — neither distress selling nor aggressive buying
No strong insider signal. Watch for changes in promoter stake as a leading indicator.
Key Watchpoints
Breaks above ₹447 (+5%)
Trend reversal confirmation
Breaks below ₹404 (-5%)
Further downside risk
PE reverts to median of 131.2 (7 quarterly points (limited history))
Valuation normalization
Pharma sector holding leadership position
Sector momentum continuing